What to Ask Before Starting a Women's Health Telehealth Program

Short answer: before you pay, confirm clinical purpose, clinician authorization in your state, evaluation depth, whether medication is FDA-approved or compounded, follow-up and urgent-care plans, total ongoing cost, and cancellation terms.

Before you hand over payment information to any Women's Health telehealth provider, there's a short list of questions worth getting real answers to. A legitimate provider should answer all of these clearly, without hedging — here's exactly what to ask.

Clinical Purpose and Diagnosis

• "Is this program for menopause hormone therapy, sexual wellness treatment, or both?" These are related but genuinely different care pathways — HRT addresses menopause symptoms and bone-loss prevention; sexual wellness care evaluates distressing low desire, which can have many causes.
• "What problem are you evaluating, and what diagnosis are you considering?" A credible answer connects treatment to your actual symptoms and history — not a promise that every patient with fatigue, brain fog, dryness, or low libido needs the same hormone or medication.

Clinician and Licensure

• "Who is my clinician, what's their credential, and are they authorized to treat me in the state where I'm located during appointments?" Telehealth rules are largely state-based — clinicians generally need authorization wherever you're physically located at the time of care.^[3]

Evaluation Depth

• "What information will you review before prescribing?" A real HRT intake covers symptoms, menstrual and reproductive history, uterus status, medications, allergies, medical and family history, prior clotting or cardiovascular events, cancer history, liver disease, unexplained bleeding, and your treatment goals.^[1]
• "How do you assess whether low desire is HSDD or something else?" A responsible sexual wellness evaluation checks whether low desire is persistent and distressing, generalized or situational, and whether pain, dryness, medications, mood, sleep, relationship factors, or menopause symptoms explain it better.^[2]
• "Do I need labs, and what specific decision will each test help make?" For most healthy women 45+ with typical symptoms, diagnosis is usually based on history — not broad routine hormone panels. A provider should explain targeted testing rather than treating estradiol, FSH, saliva, or urine testing as universally required.^[4]
• "Will you screen for conditions that need in-person care, imaging, or referral?" A provider should explain how it handles unexplained bleeding, possible pregnancy, unusually early menopause, suspected primary ovarian insufficiency, complex cardiovascular risk, or symptoms suggesting another condition.^[5]

Medication and Sourcing

• "Is the medication FDA-approved, FDA-approved but used off-label, or compounded?" These are genuinely different things and shouldn't get blended together in marketing — an FDA-approved product has a specific reviewed formulation and label; off-label means an approved product used outside that label; compounded means not an FDA-approved finished drug product at all.^[7]
• "What is the exact drug name, active ingredient, strength, dosage form, delivery route, and dosing schedule?" "Bioidentical," "natural," "custom," or "peptide" aren't real answers — you should know if it's FDA-approved estradiol, oral micronized progesterone, low-dose vaginal estrogen, branded Vyleesi, or a specifically named compounded preparation.^[8]
• "If it's compounded, why isn't a suitable FDA-approved alternative being used?" Compounding can serve a real need — an allergy to an inactive ingredient, or a dosage form that isn't commercially available — but compounded drugs aren't reviewed by the FDA before marketing for safety, effectiveness, or quality.^[6]
• "Which pharmacy fills the prescription, and can I use a different one?" The provider should disclose the pharmacy name and type (retail, mail-order, or compounding), how medication ships or gets picked up, whether it's bundled into the program fee, and who answers medication questions.
• "Does this target systemic menopause symptoms, local vaginal symptoms, or low sexual desire?" Systemic estrogen treats whole-body symptoms; low-dose vaginal estrogen targets genitourinary symptoms specifically; bremelanotide has a narrow approved indication for acquired, generalized HSDD in premenopausal women — these aren't interchangeable.^[1]

Risk and Safety

• "If I have a uterus, how will you protect my endometrium on systemic estrogen?" An intact uterus generally needs adequate progestogen alongside systemic estrogen to lower endometrial cancer risk, with the specific regimen based on the medication and your history.^[1]
• "What are the major risks, side effects, and reasons I shouldn't use this treatment?" For systemic HRT, this should cover unexplained bleeding, prior estrogen-sensitive cancer, blood clots, stroke, heart disease, and liver disease.^[1]

Follow-Up and Monitoring

• "What follow-up will happen, and what does it cost?" Guidelines call for review around three months after starting to check effectiveness and tolerability, then at least annually, with earlier follow-up if symptoms persist or side effects occur.^[4]
• "How will you monitor whether treatment is working?" A sound answer focuses on symptom response, side effects, bleeding pattern where relevant, and your changing benefit-risk balance — not a promise to chase a universal hormone number with repeated panels.
• "What happens if I develop abnormal bleeding, chest pain, shortness of breath, a severe headache, fainting, one-sided leg swelling, or stroke-like symptoms?" The program needs clear escalation instructions for genuinely urgent symptoms — these shouldn't be handled through asynchronous messaging or an automatic refill.^[9]
• "Can I get my visit notes, lab results, prescription details, and instructions?" AMA telemedicine ethics guidance calls for real documentation, continuity, and coordination — you should be able to share your care information with an in-person clinician or specialist when needed.^[3]

Cost and Exit Terms

• "What is the full financial commitment?" Get written answers on the initial evaluation, membership fees, follow-up visits, lab costs, medication, shipping, refill rules, prior authorization support, and insurance versus cash-pay handling — every charge that continues after the first month. Don't rely on a headline price alone.
• "What is the cancellation, pause, refund, and refill policy?" This varies company to company — a provider should publish it clearly before you pay, including notice requirements, whether dispensed medication is refundable, how to stop recurring billing, and whether a final clinician visit is needed for a safe transition off treatment.

The Bottom Line

The practical checklist is simple: confirm the clinical purpose, clinician authorization, evaluation depth, medication status and source, monitoring plan, total ongoing cost, and exit terms — before you provide payment information. A provider that answers all of this clearly is far easier to trust than one leaning on vague claims about "customized women's health."

Compare how different providers actually answer these exact questions before choosing where to start.

Frequently Asked Questions